 Cara Mack
Concepts (352)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biliary Atresia | 39 | 2024 | 185 | 10.860 |
Why?
| | Hepatitis, Autoimmune | 8 | 2022 | 27 | 3.880 |
Why?
| | Cholangitis, Sclerosing | 11 | 2022 | 66 | 3.810 |
Why?
| | Cytomegalovirus Infections | 4 | 2024 | 180 | 1.950 |
Why?
| | Cholestasis | 11 | 2022 | 225 | 1.940 |
Why?
| | Bile Ducts | 8 | 2020 | 68 | 1.890 |
Why?
| | Anemia, Aplastic | 2 | 2021 | 30 | 1.460 |
Why?
| | Hepatitis | 2 | 2021 | 45 | 1.460 |
Why?
| | Bile Ducts, Extrahepatic | 4 | 2021 | 24 | 1.360 |
Why?
| | Rotavirus Infections | 5 | 2013 | 50 | 1.320 |
Why?
| | B-Lymphocytes | 3 | 2019 | 766 | 1.190 |
Why?
| | Liver Diseases | 6 | 2023 | 255 | 1.170 |
Why?
| | Portoenterostomy, Hepatic | 9 | 2023 | 53 | 1.110 |
Why?
| | Immunosuppressive Agents | 7 | 2022 | 646 | 1.060 |
Why?
| | Elasticity Imaging Techniques | 3 | 2023 | 40 | 1.040 |
Why?
| | Liver Transplantation | 12 | 2022 | 707 | 1.020 |
Why?
| | Autoimmunity | 7 | 2022 | 813 | 0.950 |
Why?
| | Rotavirus | 4 | 2014 | 22 | 0.940 |
Why?
| | Liver | 13 | 2023 | 1637 | 0.900 |
Why?
| | Cytokines | 7 | 2019 | 1841 | 0.890 |
Why?
| | Infant | 28 | 2023 | 7963 | 0.840 |
Why?
| | Biliary Tract | 3 | 2019 | 16 | 0.830 |
Why?
| | Immunity, Humoral | 3 | 2013 | 112 | 0.820 |
Why?
| | Azathioprine | 3 | 2022 | 49 | 0.810 |
Why?
| | Child | 36 | 2023 | 18415 | 0.790 |
Why?
| | Liver Cirrhosis | 4 | 2022 | 227 | 0.790 |
Why?
| | Immunoglobulins, Intravenous | 3 | 2019 | 122 | 0.780 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2019 | 18 | 0.780 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2013 | 339 | 0.770 |
Why?
| | Immunoglobulin M | 2 | 2021 | 246 | 0.760 |
Why?
| | Liver Function Tests | 5 | 2023 | 103 | 0.750 |
Why?
| | Autoantibodies | 3 | 2021 | 1346 | 0.740 |
Why?
| | Th1 Cells | 4 | 2013 | 123 | 0.730 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2020 | 14 | 0.700 |
Why?
| | Disease Models, Animal | 11 | 2020 | 3535 | 0.690 |
Why?
| | Humans | 73 | 2024 | 114689 | 0.690 |
Why?
| | Gastroenterology | 3 | 2020 | 159 | 0.690 |
Why?
| | Antigen-Presenting Cells | 5 | 2019 | 150 | 0.650 |
Why?
| | Oligonucleotides | 1 | 2020 | 137 | 0.650 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 245 | 0.650 |
Why?
| | Cytomegalovirus | 3 | 2023 | 144 | 0.640 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2020 | 125 | 0.630 |
Why?
| | Adaptive Immunity | 3 | 2018 | 155 | 0.620 |
Why?
| | Genetic Therapy | 1 | 2020 | 257 | 0.620 |
Why?
| | Transplant Recipients | 1 | 2020 | 140 | 0.600 |
Why?
| | Thioguanine | 1 | 2017 | 19 | 0.580 |
Why?
| | Organ Transplantation | 1 | 2020 | 159 | 0.570 |
Why?
| | Bilirubin | 8 | 2022 | 88 | 0.570 |
Why?
| | Disease Outbreaks | 1 | 2020 | 307 | 0.560 |
Why?
| | Immunity, Innate | 2 | 2013 | 720 | 0.560 |
Why?
| | Societies, Medical | 2 | 2018 | 664 | 0.540 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2022 | 39 | 0.530 |
Why?
| | Portal Vein | 3 | 2010 | 76 | 0.530 |
Why?
| | Mice, Inbred BALB C | 7 | 2018 | 1144 | 0.510 |
Why?
| | Hyperbilirubinemia | 3 | 2017 | 14 | 0.510 |
Why?
| | Alagille Syndrome | 3 | 2022 | 35 | 0.500 |
Why?
| | Child, Preschool | 16 | 2022 | 9116 | 0.490 |
Why?
| | Liver Circulation | 2 | 2006 | 19 | 0.470 |
Why?
| | T-Lymphocytes | 4 | 2012 | 1737 | 0.470 |
Why?
| | Inflammation | 4 | 2020 | 2480 | 0.470 |
Why?
| | Postoperative Complications | 4 | 2020 | 2128 | 0.470 |
Why?
| | Cholangitis | 2 | 2015 | 19 | 0.450 |
Why?
| | Hypertension, Portal | 3 | 2021 | 61 | 0.430 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2015 | 959 | 0.430 |
Why?
| | Animals, Newborn | 5 | 2018 | 778 | 0.420 |
Why?
| | Venous Thrombosis | 2 | 2006 | 140 | 0.410 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2015 | 687 | 0.410 |
Why?
| | Interferon-gamma | 4 | 2015 | 719 | 0.410 |
Why?
| | Adolescent | 18 | 2023 | 17848 | 0.390 |
Why?
| | Reoviridae Infections | 1 | 2012 | 52 | 0.390 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2086 | 0.390 |
Why?
| | Vaccination | 1 | 2020 | 1204 | 0.390 |
Why?
| | Infant, Newborn | 12 | 2019 | 5047 | 0.380 |
Why?
| | Immunity, Cellular | 2 | 2012 | 248 | 0.370 |
Why?
| | Male | 28 | 2023 | 55599 | 0.360 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 797 | 0.360 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2010 | 30 | 0.350 |
Why?
| | Hepacivirus | 1 | 2012 | 229 | 0.350 |
Why?
| | Female | 31 | 2023 | 59511 | 0.350 |
Why?
| | Treatment Outcome | 11 | 2021 | 9088 | 0.350 |
Why?
| | Ursodeoxycholic Acid | 2 | 2021 | 20 | 0.350 |
Why?
| | Aspartate Aminotransferases | 3 | 2022 | 86 | 0.350 |
Why?
| | Biomarkers | 7 | 2022 | 3408 | 0.340 |
Why?
| | Immunoglobulin G | 1 | 2014 | 770 | 0.340 |
Why?
| | Animals | 16 | 2021 | 31706 | 0.340 |
Why?
| | Mice | 12 | 2020 | 14869 | 0.330 |
Why?
| | Hepatitis C | 1 | 2012 | 219 | 0.330 |
Why?
| | Sarcopenia | 2 | 2021 | 63 | 0.320 |
Why?
| | Glucocorticoids | 3 | 2021 | 532 | 0.310 |
Why?
| | Cell Line | 5 | 2021 | 2637 | 0.310 |
Why?
| | Pediatrics | 5 | 2020 | 980 | 0.300 |
Why?
| | Flow Cytometry | 4 | 2018 | 1083 | 0.290 |
Why?
| | Disease Progression | 6 | 2021 | 2380 | 0.290 |
Why?
| | Graft Rejection | 2 | 2021 | 513 | 0.280 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2007 | 18 | 0.280 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2014 | 1140 | 0.280 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 382 | 0.280 |
Why?
| | Retrospective Studies | 12 | 2022 | 12551 | 0.280 |
Why?
| | Failure to Thrive | 2 | 2018 | 32 | 0.280 |
Why?
| | Portal System | 2 | 2004 | 13 | 0.270 |
Why?
| | Histocompatibility Antigens | 2 | 2022 | 98 | 0.270 |
Why?
| | Macaca mulatta | 1 | 2007 | 131 | 0.270 |
Why?
| | Mesenteric Veins | 1 | 2006 | 9 | 0.260 |
Why?
| | Bile Acids and Salts | 3 | 2022 | 171 | 0.260 |
Why?
| | gamma-Glutamyltransferase | 3 | 2021 | 42 | 0.250 |
Why?
| | Epithelium | 1 | 2006 | 295 | 0.250 |
Why?
| | Anastomosis, Roux-en-Y | 1 | 2005 | 25 | 0.240 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2004 | 48 | 0.230 |
Why?
| | Cardiovirus Infections | 1 | 2003 | 3 | 0.220 |
Why?
| | Theilovirus | 1 | 2003 | 5 | 0.220 |
Why?
| | Fetal Diseases | 1 | 2005 | 147 | 0.220 |
Why?
| | Autoantigens | 2 | 2022 | 396 | 0.220 |
Why?
| | Hepatopulmonary Syndrome | 2 | 2017 | 24 | 0.220 |
Why?
| | Butyrates | 2 | 2022 | 53 | 0.220 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 25 | 0.220 |
Why?
| | Portasystemic Shunt, Surgical | 1 | 2003 | 4 | 0.210 |
Why?
| | Benzodiazepines | 2 | 2022 | 116 | 0.210 |
Why?
| | Antigen Presentation | 2 | 2019 | 188 | 0.200 |
Why?
| | Neonatal Screening | 2 | 2015 | 152 | 0.200 |
Why?
| | Hepatitis C, Chronic | 2 | 2015 | 151 | 0.200 |
Why?
| | Transaminases | 1 | 2021 | 24 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1342 | 0.190 |
Why?
| | Microglia | 1 | 2003 | 202 | 0.190 |
Why?
| | Transforming Growth Factor beta | 2 | 2019 | 448 | 0.190 |
Why?
| | Hepatocytes | 2 | 2020 | 195 | 0.190 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 75 | 0.190 |
Why?
| | Fontan Procedure | 1 | 2023 | 157 | 0.190 |
Why?
| | Immunohistochemistry | 3 | 2018 | 1629 | 0.180 |
Why?
| | Malnutrition | 1 | 2021 | 62 | 0.180 |
Why?
| | Syndrome | 1 | 2021 | 333 | 0.180 |
Why?
| | Horses | 1 | 2021 | 96 | 0.180 |
Why?
| | Organic Anion Transporters, Sodium-Dependent | 1 | 2020 | 28 | 0.180 |
Why?
| | Exercise Test | 1 | 2023 | 544 | 0.180 |
Why?
| | Blood Coagulation Disorders | 1 | 2003 | 197 | 0.180 |
Why?
| | Abnormalities, Multiple | 2 | 2013 | 178 | 0.180 |
Why?
| | Symporters | 1 | 2020 | 52 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 1 | 2021 | 397 | 0.170 |
Why?
| | Vancomycin | 1 | 2021 | 75 | 0.170 |
Why?
| | Prednisolone | 1 | 2020 | 75 | 0.170 |
Why?
| | Tacrolimus | 1 | 2021 | 134 | 0.170 |
Why?
| | Adoptive Transfer | 2 | 2013 | 195 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2020 | 158 | 0.170 |
Why?
| | Inflammatory Bowel Diseases | 2 | 2021 | 284 | 0.170 |
Why?
| | Preoperative Period | 1 | 2020 | 103 | 0.170 |
Why?
| | Vaccination Refusal | 1 | 2020 | 69 | 0.160 |
Why?
| | Colitis, Ulcerative | 1 | 2020 | 105 | 0.160 |
Why?
| | Cell Transdifferentiation | 1 | 2019 | 31 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.160 |
Why?
| | Cognition | 1 | 2006 | 989 | 0.160 |
Why?
| | Respiratory Tract Diseases | 1 | 2000 | 138 | 0.150 |
Why?
| | Safety | 1 | 2000 | 297 | 0.150 |
Why?
| | Drainage | 1 | 2019 | 151 | 0.150 |
Why?
| | Prospective Studies | 5 | 2023 | 6220 | 0.150 |
Why?
| | Bile Duct Diseases | 1 | 2018 | 15 | 0.150 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2018 | 15 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2020 | 195 | 0.150 |
Why?
| | Self Expandable Metallic Stents | 1 | 2018 | 14 | 0.150 |
Why?
| | Pruritus | 3 | 2022 | 59 | 0.150 |
Why?
| | Interleukin-2 | 3 | 2015 | 413 | 0.150 |
Why?
| | Liver Failure, Acute | 2 | 2009 | 58 | 0.140 |
Why?
| | Maintenance Chemotherapy | 1 | 2017 | 22 | 0.140 |
Why?
| | Counseling | 1 | 2000 | 342 | 0.140 |
Why?
| | Enterohepatic Circulation | 1 | 2017 | 7 | 0.140 |
Why?
| | Alanine Transaminase | 2 | 2021 | 142 | 0.140 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 56 | 0.140 |
Why?
| | Follow-Up Studies | 4 | 2019 | 4411 | 0.140 |
Why?
| | Jaundice, Obstructive | 1 | 2017 | 3 | 0.140 |
Why?
| | History, 20th Century | 1 | 2018 | 264 | 0.140 |
Why?
| | Heart Defects, Congenital | 1 | 2023 | 671 | 0.140 |
Why?
| | Morbidity | 1 | 2017 | 280 | 0.140 |
Why?
| | Proteins | 1 | 2022 | 908 | 0.140 |
Why?
| | Spleen | 1 | 2018 | 487 | 0.130 |
Why?
| | Digestive System Surgical Procedures | 1 | 2017 | 91 | 0.130 |
Why?
| | Virus Diseases | 2 | 2013 | 195 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 385 | 0.130 |
Why?
| | Models, Statistical | 1 | 2020 | 599 | 0.130 |
Why?
| | Risk Assessment | 3 | 2020 | 2968 | 0.130 |
Why?
| | Cell Culture Techniques | 1 | 2018 | 343 | 0.130 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2018 | 180 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2015 | 3886 | 0.130 |
Why?
| | End Stage Liver Disease | 1 | 2017 | 63 | 0.130 |
Why?
| | Enterostomy | 1 | 2015 | 8 | 0.130 |
Why?
| | Global Health | 1 | 2017 | 287 | 0.120 |
Why?
| | Cell Separation | 2 | 2008 | 291 | 0.120 |
Why?
| | Biopsy | 3 | 2020 | 1036 | 0.120 |
Why?
| | Firearms | 1 | 2000 | 297 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 497 | 0.120 |
Why?
| | Leadership | 1 | 2018 | 292 | 0.120 |
Why?
| | Preoperative Care | 1 | 2017 | 319 | 0.120 |
Why?
| | MicroRNAs | 1 | 2020 | 600 | 0.110 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 35 | 0.110 |
Why?
| | Albumins | 1 | 2014 | 89 | 0.110 |
Why?
| | Macrophages | 3 | 2005 | 1263 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2020 | 615 | 0.110 |
Why?
| | Time Factors | 5 | 2021 | 6116 | 0.110 |
Why?
| | Risk Factors | 5 | 2021 | 8632 | 0.110 |
Why?
| | Algorithms | 1 | 2020 | 1469 | 0.110 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 116 | 0.100 |
Why?
| | Cholestasis, Extrahepatic | 1 | 2012 | 5 | 0.100 |
Why?
| | Hepatolenticular Degeneration | 1 | 2012 | 16 | 0.100 |
Why?
| | Pregnancy | 3 | 2013 | 5518 | 0.100 |
Why?
| | Choledochal Cyst | 1 | 2012 | 17 | 0.100 |
Why?
| | Gallstones | 1 | 2012 | 28 | 0.100 |
Why?
| | Biliary Tract Diseases | 1 | 2012 | 32 | 0.100 |
Why?
| | Hepatitis A | 1 | 2012 | 26 | 0.100 |
Why?
| | Young Adult | 3 | 2023 | 10470 | 0.100 |
Why?
| | Hypertension, Pulmonary | 2 | 2015 | 1729 | 0.100 |
Why?
| | Colorado | 1 | 2021 | 4099 | 0.090 |
Why?
| | Case-Control Studies | 3 | 2015 | 3003 | 0.090 |
Why?
| | Heterotaxy Syndrome | 1 | 2010 | 10 | 0.090 |
Why?
| | Serum Albumin | 2 | 2021 | 137 | 0.090 |
Why?
| | Viral Proteins | 1 | 2012 | 281 | 0.090 |
Why?
| | Immunoblotting | 1 | 2010 | 283 | 0.080 |
Why?
| | Prognosis | 4 | 2020 | 3329 | 0.080 |
Why?
| | Predictive Value of Tests | 3 | 2020 | 1796 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2005 | 801 | 0.080 |
Why?
| | Hemochromatosis | 1 | 2009 | 9 | 0.080 |
Why?
| | Exchange Transfusion, Whole Blood | 1 | 2009 | 15 | 0.080 |
Why?
| | Graft Survival | 2 | 2022 | 446 | 0.080 |
Why?
| | Rats | 2 | 2007 | 4958 | 0.080 |
Why?
| | RNA, Messenger | 3 | 2005 | 2553 | 0.080 |
Why?
| | Internationality | 2 | 2021 | 143 | 0.080 |
Why?
| | Epigenesis, Genetic | 1 | 2013 | 520 | 0.080 |
Why?
| | Survival Analysis | 2 | 2017 | 1211 | 0.080 |
Why?
| | Mice, Transgenic | 1 | 2013 | 1949 | 0.070 |
Why?
| | Liver Failure | 1 | 2008 | 75 | 0.070 |
Why?
| | Chemokines | 1 | 2008 | 216 | 0.070 |
Why?
| | Reoviridae | 1 | 2007 | 35 | 0.070 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2007 | 25 | 0.070 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 149 | 0.070 |
Why?
| | Quality of Life | 3 | 2022 | 2353 | 0.070 |
Why?
| | Immunologic Factors | 1 | 2009 | 220 | 0.070 |
Why?
| | Oligoclonal Bands | 1 | 2007 | 21 | 0.070 |
Why?
| | Histocompatibility Testing | 1 | 2007 | 116 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2007 | 73 | 0.070 |
Why?
| | Hepatitis, Viral, Human | 1 | 2006 | 25 | 0.070 |
Why?
| | CD3 Complex | 1 | 2006 | 92 | 0.070 |
Why?
| | Virus Replication | 1 | 2008 | 395 | 0.070 |
Why?
| | Influenza A virus | 1 | 2006 | 90 | 0.060 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2540 | 0.060 |
Why?
| | Fibrosis | 2 | 2005 | 453 | 0.060 |
Why?
| | Mice, SCID | 1 | 2006 | 314 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 136 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2005 | 84 | 0.060 |
Why?
| | Analysis of Variance | 2 | 2019 | 1226 | 0.060 |
Why?
| | Sialoglycoproteins | 1 | 2005 | 159 | 0.060 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2005 | 157 | 0.060 |
Why?
| | In Vitro Techniques | 1 | 2006 | 1016 | 0.060 |
Why?
| | Pulmonary Artery | 1 | 2010 | 1016 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 923 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2005 | 209 | 0.060 |
Why?
| | United States | 2 | 2018 | 12183 | 0.060 |
Why?
| | Parenteral Nutrition, Total | 1 | 2004 | 27 | 0.060 |
Why?
| | Kupffer Cells | 1 | 2004 | 45 | 0.060 |
Why?
| | Protein S | 1 | 2003 | 5 | 0.050 |
Why?
| | Antithrombin III | 1 | 2003 | 7 | 0.050 |
Why?
| | Factor V | 1 | 2003 | 22 | 0.050 |
Why?
| | Prothrombin | 1 | 2003 | 22 | 0.050 |
Why?
| | Adult | 3 | 2020 | 30550 | 0.050 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2023 | 47 | 0.050 |
Why?
| | Prothrombin Time | 1 | 2003 | 34 | 0.050 |
Why?
| | Paralysis | 1 | 2003 | 66 | 0.050 |
Why?
| | Factor VII | 1 | 2003 | 26 | 0.050 |
Why?
| | Partial Thromboplastin Time | 1 | 2003 | 51 | 0.050 |
Why?
| | Mice, Inbred Strains | 1 | 2003 | 396 | 0.050 |
Why?
| | Factor VIII | 1 | 2003 | 53 | 0.050 |
Why?
| | Endoglin | 1 | 2022 | 20 | 0.050 |
Why?
| | Seasons | 1 | 2005 | 442 | 0.050 |
Why?
| | Protein C | 1 | 2003 | 45 | 0.050 |
Why?
| | Attention | 1 | 2006 | 393 | 0.050 |
Why?
| | Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2003 | 170 | 0.050 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2003 | 80 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1760 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2005 | 610 | 0.050 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2004 | 740 | 0.050 |
Why?
| | Cohort Studies | 3 | 2019 | 4895 | 0.050 |
Why?
| | Neuropsychological Tests | 1 | 2006 | 927 | 0.050 |
Why?
| | Interleukin-8 | 1 | 2022 | 237 | 0.050 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2022 | 122 | 0.050 |
Why?
| | Spinal Cord | 1 | 2003 | 347 | 0.050 |
Why?
| | Cholangiography | 1 | 2020 | 17 | 0.050 |
Why?
| | Drug Resistance | 1 | 2021 | 158 | 0.050 |
Why?
| | Influenza, Human | 1 | 2006 | 546 | 0.050 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.050 |
Why?
| | CD79 Antigens | 1 | 2020 | 16 | 0.040 |
Why?
| | Fatigue | 1 | 2022 | 294 | 0.040 |
Why?
| | Phenotype | 2 | 2005 | 2796 | 0.040 |
Why?
| | Protective Agents | 1 | 2020 | 37 | 0.040 |
Why?
| | Enteral Nutrition | 1 | 2021 | 160 | 0.040 |
Why?
| | Gastrointestinal Agents | 1 | 2020 | 60 | 0.040 |
Why?
| | Propensity Score | 1 | 2021 | 224 | 0.040 |
Why?
| | Survival Rate | 2 | 2017 | 1644 | 0.040 |
Why?
| | Cell Movement | 1 | 2003 | 869 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 287 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2020 | 192 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 728 | 0.040 |
Why?
| | Cephalometry | 1 | 2018 | 28 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 935 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1373 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 430 | 0.040 |
Why?
| | Models, Biological | 1 | 2005 | 1621 | 0.040 |
Why?
| | Treatment Failure | 1 | 2019 | 331 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 811 | 0.040 |
Why?
| | Japan | 1 | 2017 | 86 | 0.040 |
Why?
| | Jaundice | 1 | 2017 | 14 | 0.030 |
Why?
| | Emotional Adjustment | 1 | 2017 | 17 | 0.030 |
Why?
| | Postoperative Care | 1 | 2018 | 222 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 743 | 0.030 |
Why?
| | Societies | 1 | 2017 | 38 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2017 | 182 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2018 | 249 | 0.030 |
Why?
| | Carrier Proteins | 1 | 2020 | 695 | 0.030 |
Why?
| | Family Relations | 1 | 2017 | 85 | 0.030 |
Why?
| | Apoptosis | 1 | 2005 | 2363 | 0.030 |
Why?
| | Europe | 1 | 2017 | 334 | 0.030 |
Why?
| | North America | 1 | 2017 | 256 | 0.030 |
Why?
| | Hemorrhage | 1 | 2000 | 620 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 620 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2015 | 92 | 0.030 |
Why?
| | Waiting Lists | 1 | 2017 | 211 | 0.030 |
Why?
| | Receptors, Immunologic | 1 | 2015 | 201 | 0.030 |
Why?
| | Mutation | 1 | 2005 | 3346 | 0.030 |
Why?
| | Pneumonia | 1 | 2000 | 568 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 2894 | 0.030 |
Why?
| | Child Development | 1 | 2018 | 385 | 0.030 |
Why?
| | Body Weight | 1 | 2018 | 869 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2018 | 1660 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2020 | 2570 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2015 | 194 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1768 | 0.030 |
Why?
| | Health Policy | 1 | 2017 | 334 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1430 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 701 | 0.030 |
Why?
| | Exercise | 1 | 2023 | 1644 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2765 | 0.030 |
Why?
| | Parents | 1 | 2000 | 1186 | 0.030 |
Why?
| | Brain | 1 | 2003 | 2371 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2015 | 1037 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2320 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2017 | 763 | 0.020 |
Why?
| | Dilatation, Pathologic | 1 | 2010 | 55 | 0.020 |
Why?
| | Osteopontin | 1 | 2005 | 32 | 0.020 |
Why?
| | DNA, Complementary | 1 | 2005 | 256 | 0.010 |
Why?
| | Patient Selection | 1 | 2008 | 641 | 0.010 |
Why?
| | Genomic Imprinting | 1 | 2004 | 32 | 0.010 |
Why?
| | Influenza Vaccines | 1 | 2006 | 497 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2114 | 0.010 |
Why?
| | Cell Cycle Proteins | 1 | 2004 | 551 | 0.010 |
Why?
| | Gene Expression | 1 | 2005 | 1421 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2005 | 951 | 0.010 |
Why?
|
|
Mack's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|